Horizon Therapeutics Plc - HZNP STOCK NEWS

Xeris Biopharma Holdings (XERS) has partnered with Horizon Therapeutics (HZNP) to develop an ultra-concentrated, ready-to-use subcutaneous injection of teprotumumab, FDA-approved for Thyroid Eye Disease. The agreement utilizes Xeris' proprietary XeriJect technology, enhancing patient treatment experience. Xeris will receive an upfront payment and may earn additional milestone payments and royalties if the technology is licensed. This collaboration aims to improve drug delivery and patient adherence. No specific financial terms were disclosed.

Horizon Therapeutics has completed enrollment in the Phase 3 OPTIC-J trial in Japan, evaluating TEPEZZA for active Thyroid Eye Disease (TED), an autoimmune condition that can cause serious vision issues. This trial is crucial as TEPEZZA is the first treatment for TED approved by the FDA, but it is not yet available in Japan. The trial aims to assess the drug's efficacy, safety, and tolerability among Japanese patients. Successful outcomes could lead to a potential market entry, addressing the significant unmet medical need for TED therapy in Japan.

Horizon Therapeutics has announced a multi-year collaboration with Johns Hopkins University School of Medicine to explore new therapies for autoimmune and inflammatory diseases. The partnership will initially focus on immunometabolism, aiming to identify metabolic pathways that contribute to conditions like myositis. This collaboration coincides with Horizon's expansion in Maryland, where it will become the first tenant at the Alexandria Center at Traville Gateway, promoting job growth and new therapeutic developments.

Horizon Therapeutics plc (Nasdaq: HZNP) will participate in two major healthcare conferences in November 2022. The Stifel 2022 Healthcare Conference will take place on November 15 at 1:15 p.m. ET in New York, NY. The Piper Sandler 34th Annual Healthcare Conference is scheduled for November 30 at 9:30 a.m. ET, also in New York, NY. Both presentations will be webcast live and available for replay on Horizon's website for one year.

Horizon Therapeutics announced that Month 12 results from the MIRROR randomized controlled trial will be presented on Nov. 13, 11:45 a.m. EST. The trial demonstrated that 60% of patients treated with KRYSTEXXA and methotrexate maintained serum uric acid levels below 6 mg/dL. Imaging analyses indicated a 95% reduction in uric acid deposits, highlighting the efficacy of the treatment. Notably, 53.8% of patients with tophi showed complete resolution. These findings reinforce the therapeutic benefits of KRYSTEXXA co-administered with methotrexate for uncontrolled gout.

Horizon Therapeutics released new findings from the MIRROR randomized controlled trial, presented at ASN Kidney Week 2022, showing that KRYSTEXXA (pegloticase) combined with methotrexate effectively treats uncontrolled gout without compromising kidney function. The study revealed a significant improvement in estimated glomerular filtration rate (eGFR) in patients receiving methotrexate. Over 30% of patients demonstrated stable eGFR levels, and 71% of those treated with KRYSTEXXA and methotrexate achieved a sustained urate-lowering response, indicating promising benefits for patients with chronic kidney disease.

Horizon Therapeutics reported third-quarter 2022 net sales of $925.4 million, down from $1.037 billion in Q3 2021. GAAP net income was $135.8 million, a 58% decline year-over-year. TEPEZZA generated $490.9 million in sales, while KRYSTEXXA saw a 21% increase to $191.6 million. The company raised its full-year net sales guidance to between $3.59 billion and $3.61 billion, projecting high-teens growth for TEPEZZA and 25% growth for KRYSTEXXA. Cash reserves stood at $2.13 billion as of September 30, 2022.

Horizon Therapeutics (Nasdaq: HZNP) has been recognized in Seramount’s 2022 Inclusion Index, highlighting its commitment to diversity, equity, and inclusion (DEI). This acknowledgment reflects the company’s initiatives in recruiting and supporting underrepresented groups, including women and racial/ethnic minorities. Executive VP Irina Konstantinovsky emphasized the importance of an inclusive workplace for creative collaboration. Horizon has earned over 65 awards since 2015 for its workplace culture, demonstrating its ongoing dedication to DEI best practices.

Horizon Therapeutics (HZNP) and Q32 Bio announced the dosing of the first patient in a Phase 2 trial for ADX-914, an anti-IL-7Rα antibody targeting moderate-to-severe atopic dermatitis. This pivotal study aims to evaluate ADX-914's safety and efficacy, with a focus on restoring immune function. Following a successful Phase 1 trial demonstrating its pharmacological effect, this collaboration signifies a crucial milestone in developing innovative treatments for autoimmune diseases. Horizon is funding the development, with plans for a second Phase 2 trial in another autoimmune indication.